Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.
HIV‐1
bNAbs (broadly neutralizing antibodies
drug resistance mutations
fostemsavir
lenacapavir
primary infection
teropavimab
zinlirvimab
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
03
09
2024
received:
17
06
2024
accepted:
23
09
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
ppublish
Résumé
Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV-1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic-based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long-acting drugs such as lenacapavir and bNAbs.
Substances chimiques
Antibodies, Neutralizing
0
Anti-HIV Agents
0
fostemsavir
97IQ273H4L
Organophosphates
0
HIV Antibodies
0
Piperazines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29948Informations de copyright
© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Visseaux B, Assoumou L, Mahjoub N, et al. Surveillance of HIV‐1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence? J Antimicrob Chemother. 2020;75:183‐193. doi:10.1093/jac/dkz404
Chaix ML, Seng R, Frange P, et al. Increasing HIV‐1 non‐B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis. 2013;56:880‐887. doi:10.1093/cid/cis999
Frange P, Assoumou L, Descamps D, et al. HIV‐1 subtype B‐infected MSM may have driven the spread of transmitted resistant strains in France in 2007‐12: impact on susceptibility to first‐line strategies. J Antimicrob Chemother. 2015;70(7):2084‐2089. doi:10.1093/jac/dkv049
Andreis S, Basso M, Scaggiante R, et al. Drug resistance in B and non‐B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV‐infected over the period 2013‐2016: impact on susceptibility to first‐line strategies including integrase strand‐transfer inhibitors. J Global Antimicrob Resist. 2017;10:106‐112. doi:10.1016/j.jgar.2017.05.011
Casadellà M, Santos JR, Noguera‐Julian M, et al. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV‐1 genotyping. J Antimicrob Chemother. 2020;75(12):3517‐3524. doi:10.1093/jac/dkaa349
Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol. 2006;78(2):153‐160. doi:10.1002/jmv.20522
Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context‐based modeling for ultrafast HIV‐1 subtype identification. Nucleic Acids Res. 2014;42(18):e144. doi:10.1093/nar/gku739
Margot N, Vanderveen L, Naik V, et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof‐of‐concept clinical study. J Antimicrob Chemother. 2022;77(4):989‐995. doi:10.1093/jac/dkab503
Nka AD, Bouba Y, Teto G, et al. Evaluation of HIV‐1 capsid genetic variability and lenacapavir (GS‐6207) drug resistance‐associated mutations according to viral clades among drug‐naive individuals. J Antimicrob Chemother. 2022;78(1):272‐275. doi:10.1093/jac/dkac388
Tao K, Zhou J, Nagarajan P, Tzou PL, Shafer RW. Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments. Antiviral Res. 2024;230:105988. doi:10.1016/j.antiviral.2024.105988
Zhou N, Nowicka‐Sans B, McAuliffe B, et al. Genotypic correlates of susceptibility to HIV‐1 attachment inhibitor BMS‐626529, the active agent of the prodrug BMS‐663068. J Antimicrob Chemother. 2014;69(3):573‐581. doi:10.1093/jac/dkt412
Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV‐1 attachment inhibitor prodrug fostemsavir in heavily treatment‐experienced individuals: week 96 results of the phase 3 BRIGHTE study. The Lancet HIV. 2020;7(11):e740‐e751. doi:10.1016/S2352-3018(20)30240-X
Lataillade M, Zhou N, Joshi SR, et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV‐1 attachment inhibitor prodrug, fostemsavir. JAIDS J Acquir Immune Defic Syndr. 2018;77(3):299‐307. doi:10.1097/QAI.0000000000001602
Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV‐1 attachment inhibitor BMS‐626529 during 8‐day monotherapy with its prodrug BMS‐663068. JAIDS J Acquir Immune Defic Syndr. 2013;64(1):7‐15. doi:10.1097/QAI.0b013e31829726f3
Gartland M, Cahn P, DeJesus E, et al. Week 96 genotypic and phenotypic results of the Fostemsavir phase 3 BRIGHTE study in heavily treatment‐experienced adults living with multidrug‐resistant HIV‐1. Antimicrob Agents Chemother. 2022;66(6):e0175121. doi:10.1128/aac.01751-21
Selzer L, VanderVeen LA, Parvangada A, et al. [POSTER] Susceptibility Screening to bNAbs Teropavimab (GS‐5423) and Zinlirvimab (GS‐2872) 580 in ART‐Suppressed Participants. Published online. 2023.
Moldt B, Parvangada A, Martin R, et al. Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials. JAIDS J Acquir Immune Defic Syndr. 2021;88(1):61‐69. doi:10.1097/QAI.0000000000002722
Margot N, Pennetzdorfer N, Naik V, Rhee M, Callebaut C. Cross‐resistance to entry inhibitors and lenacapavir resistance through week 52 in study CAPELLA. Antivir Ther. 2023;28(6):13596535231220754. doi:10.1177/13596535231220754
Gartland M, Arnoult E, Foley BT, et al. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV‐1 in the Los Alamos National Laboratory HIV Sequence Database. J Antimicrob Chemother. 2021;76(11):2958‐2964. doi:10.1093/jac/dkab257
Alessandri‐Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC. Impact of natural polymorphisms of HIV‐1 non‐group M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother. 2018;73(10):2716‐2720. doi:10.1093/jac/dky271
Schader SM, Colby‐Germinario SP, Quashie PK, et al. HIV gp120 H375 is unique to HIV‐1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS‐599793, a candidate microbicide drug. Antimicrob Agents Chemother. 2012;56(8):4257‐4267. doi:10.1128/AAC.00639-12
Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341‐345. doi:10.1097/COH.0000000000000469
Soulie C, Lambert‐Niclot S, Fofana DB, et al. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS‐626529 in R5‐ and X4‐tropic HIV‐1 subtype B. J Antimicrob Chemother. 2013;68(6):1243‐1245. doi:10.1093/jac/dkt018
Bouba Y, Berno G, Fabeni L, et al. Identification of gp120 polymorphisms in HIV‐1 B subtype potentially associated with resistance to fostemsavir. J Antimicrob Chemother. 2020;75(7):1778‐1786. doi:10.1093/jac/dkaa073
Bouvin‐Pley M, Beretta M, Moreau A, et al. Evolution of the envelope glycoprotein of HIV‐1 clade B toward higher infectious properties over the course of the epidemic. J Virol. 2019;93(6). doi:10.1128/JVI.01171-18
Rose R, Gartland M, Li Z, et al. Clinical evidence for a lack of cross‐resistance between temsavir and ibalizumab or maraviroc. AIDS. 2022;36(1):11‐18. doi:10.1097/QAD.0000000000003097
Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV‐1 infection. AIDS. 2014;28(2):163‐169. doi:10.1097/QAD.0000000000000106
Liao HX, Lynch R, Zhou T. Search results ‐ PubMed. Accessed March 4, 2024. https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/?term=Liao+HX%2C+Lynch+R%2C+Zhou+T%2C&sort=date
Caskey M, Klein F, Lorenzi JCC, et al. Viraemia suppressed in HIV‐1‐infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487‐491. doi:10.1038/nature14411
Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV‐1 infection. Sci Transl Med. 2015;7(319):319ra206. doi:10.1126/scitranslmed.aad5752
Caskey M, Schoofs T, Gruell H, et al. Antibody 10‐1074 suppresses viremia in HIV‐1‐infected individuals. Nature Med. 2017;23(2):185‐191. doi:10.1038/nm.4268
Scheid JF, Horwitz JA, Bar‐On Y, et al. HIV‐1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556‐560. doi:10.1038/nature18929
Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375(21):2037‐2050. doi:10.1056/NEJMoa1608243
Cohen YZ, Butler AL, Millard K, et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti‐HIV‐1 antibodies 3BNC117 and 10‐1074 in healthy adults: a randomized, phase 1 study. PLoS One. 2019;14(8):e0219142. doi:10.1371/journal.pone.0219142
Bar‐On Y, Gruell H, Schoofs T, et al. Safety and antiviral activity of combination HIV‐1 broadly neutralizing antibodies in viremic individuals. Nature Med. 2018;24(11):1701‐1707. doi:10.1038/s41591-018-0186-4
Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti‐HIV‐1 antibodies maintains viral suppression. Nature. 2018;561(7724):479‐484. doi:10.1038/s41586-018-0531-2
Sneller MC, Blazkova J, Justement JS, et al. Combination anti‐HIV antibodies provide sustained virological suppression. Nature. 2022;606(7913):375‐381. doi:10.1038/s41586-022-04797-9
Mouquet H, Scharf L, Euler Z, et al. Complex‐type N‐glycan recognition by potent broadly neutralizing HIV antibodies. Proc Nat Acad Sci. 2012;109(47):E3268‐E3277. doi:10.1073/pnas.1217207109
Sok D, Pauthner M, Briney B, et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity. 2016;45(1):31‐45. doi:10.1016/j.immuni.2016.06.026
Barnes CO, Gristick HB, Freund NT, et al. Structural characterization of a highly‐potent V3‐glycan broadly neutralizing antibody bound to natively‐glycosylated HIV‐1 envelope. Nat Commun. 2018;9(1):1251. doi:10.1038/s41467-018-03632-y
Stefic K, Bouvin‐Pley M, Essat A, et al. Sensitivity to broadly neutralizing antibodies of recently transmitted HIV‐1 clade CRF02_AG viruses with a focus on evolution over time. J Virol. 2019;93(2). doi:10.1128/JVI.01492-18
Bunnik EM, Euler Z, Welkers MRA, et al. Adaptation of HIV‐1 envelope gp120 to humoral immunity at a population level. Nature Med. 2010;16(9):995‐997. doi:10.1038/nm.2203
Eron JJ, Little SJ, Crofoot G, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof‐of‐concept study. The Lancet HIV. 2024;11(3):e146‐e155. doi:10.1016/S2352-3018(23)00293-X